REGN-COV2
E579612
REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
All labels observed (7)
How this entity was disambiguated
This entity first appeared as the object of triple T6251190 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: REGN-COV2 Context triple: [Regeneron Pharmaceuticals, developed, REGN-COV2]
-
A.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
B.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
C.
Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
-
D.
Moderna
Moderna is a biotechnology company best known for pioneering mRNA-based vaccines, including one of the first widely used COVID-19 vaccines.
-
E.
Pfizer–BioNTech
Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: REGN-COV2 Target entity description: REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
-
A.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
B.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
C.
Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
-
D.
Moderna
Moderna is a biotechnology company best known for pioneering mRNA-based vaccines, including one of the first widely used COVID-19 vaccines.
-
E.
Pfizer–BioNTech
Pfizer–BioNTech is a pharmaceutical partnership best known for developing one of the first widely authorized mRNA vaccines against COVID-19.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 therapeutic
ⓘ
antiviral agent ⓘ monoclonal antibody cocktail ⓘ |
| administeredTo | non-hospitalized COVID-19 patients at high risk for severe disease ⓘ |
| alsoKnownAs |
REGEN-COV
ⓘ
linked to:
REGN-COV2
REGN-COV ⓘ
linked to:
REGN-COV2
REGN10933 and REGN10987 cocktail ⓘ |
| antibodyType | fully human monoclonal antibody ⓘ |
| belongsToClass |
combination monoclonal antibody therapies
ⓘ
neutralizing monoclonal antibodies ⓘ |
| clinicalTrialPhase |
Phase 1
ⓘ
Phase 2 ⓘ Phase 3 ⓘ |
| composition | fixed-dose combination of casirivimab and imdevimab ⓘ |
| designStrategy | antibody cocktail targeting non-overlapping epitopes ⓘ |
| developedBy | Regeneron Pharmaceuticals ⓘ |
| developedFor |
post-exposure prophylaxis of COVID-19
ⓘ
pre-exposure prophylaxis of COVID-19 in certain populations ⓘ treatment of mild to moderate COVID-19 ⓘ |
| discoveredUsing |
Regeneron VelocImmune platform
ⓘ
linked to:
VelocImmune technology
|
| effectiveAgainst |
early SARS-CoV-2 variants such as D614G
ⓘ
early SARS-CoV-2 variants such as original Wuhan strain ⓘ |
| EUAGrantedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| EUAIndication |
post-exposure prophylaxis of COVID-19 in certain individuals
ⓘ
treatment of mild to moderate COVID-19 in high-risk outpatients ⓘ |
| EUAStatus | EUA later revoked or withdrawn in the United States due to variant resistance ⓘ |
| hasComponent |
casirivimab
ⓘ
imdevimab ⓘ |
| hasDrugName |
casirivimab and imdevimab
ⓘ
linked to:
REGN-COV2
|
| indication |
prevention of COVID-19
ⓘ
treatment of COVID-19 ⓘ |
| mechanismOfAction |
blocks interaction between SARS-CoV-2 spike protein and ACE2 receptor
ⓘ
neutralizes SARS-CoV-2 by binding spike protein ⓘ |
| notIndicatedFor | patients requiring mechanical ventilation ⓘ |
| patentHolder | Regeneron Pharmaceuticals ⓘ |
| rationale | use of two antibodies reduces risk of viral escape mutations ⓘ |
| reducedEffectivenessAgainst |
Omicron variant of SARS-CoV-2
ⓘ
linked to:
Omicron variant
some later SARS-CoV-2 variants ⓘ |
| regulatoryStatus | received Emergency Use Authorization from U.S. FDA ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| targetOrganism | human ⓘ |
| targets |
SARS-CoV-2
ⓘ
SARS-CoV-2 spike protein ⓘ
linked to:
SARS-CoV-2 spike glycoprotein
receptor-binding domain of SARS-CoV-2 spike protein ⓘ |
| trialOutcome |
reduced COVID-19-related medical visits in high-risk outpatients
ⓘ
reduced risk of symptomatic infection in prophylaxis studies ⓘ reduced viral load in treated patients compared with placebo ⓘ |
| usedDuring | COVID-19 pandemic ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: REGN-COV2 Description of subject: REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
Referenced by (7)
Full triples — surface form annotated when it differs from this entity's canonical label.
George D. Yancopoulos
→
notableWork
→
Regeneron’s COVID‑19 antibody cocktail (REGEN‑COV / casirivimab and imdevimab)
ⓘ
linked to: REGN-COV2
linked to: REGN-COV2
linked to: REGN-COV2
linked to: REGN-COV2
linked to: REGN-COV2
linked to: REGN-COV2